Highland who? Biotech gets a $200M war chest to crack the US ADHD market
At several points last year, Toronto-based Highland Therapeutics spotlighted data from a pair of pivotal Phase III studies of Benjorna (HLD-200) which they say provided clear evidence that a nightly dose of the drug upped the performance of kids with ADHD from morning through night. Now, staring down a July 30 PDUFA date with the FDA, the low-profile biotech has raised $200 million to fund the commercial ramp-up, confident that they’re now a few short steps from shaking up a major market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.